South Korea · Delayed Price · Currency is KRW KoBioLabs Statistics
Total Valuation
KoBioLabs has a market cap or net worth of KRW 56.51 billion. The enterprise value is 41.82 billion.
| Market Cap | 56.51B |
| Enterprise Value | 41.82B |
Important Dates
The next estimated earnings date is Friday, November 13, 2026.
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
KoBioLabs has 19.42 million shares outstanding. The number of shares has increased by 0.40% in one year.
| Current Share Class | 19.42M |
| Shares Outstanding | 19.42M |
| Shares Change (YoY) | +0.40% |
| Shares Change (QoQ) | +0.06% |
| Owned by Insiders (%) | 29.87% |
| Owned by Institutions (%) | 0.07% |
| Float | 13.57M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.75 |
| PB Ratio | 1.24 |
| P/TBV Ratio | 2.02 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.55 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.39, with a Debt / Equity ratio of 0.37.
| Current Ratio | 3.39 |
| Quick Ratio | 2.87 |
| Debt / Equity | 0.37 |
| Debt / EBITDA | n/a |
| Debt / FCF | -5.89 |
| Interest Coverage | -16.70 |
Financial Efficiency
Return on equity (ROE) is -10.02% and return on invested capital (ROIC) is -8.00%.
| Return on Equity (ROE) | -10.02% |
| Return on Assets (ROA) | -5.47% |
| Return on Invested Capital (ROIC) | -8.00% |
| Return on Capital Employed (ROCE) | -10.95% |
| Weighted Average Cost of Capital (WACC) | 4.40% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.82 |
| Inventory Turnover | 2.96 |
Taxes
In the past 12 months, KoBioLabs has paid 39.54 million in taxes.
| Income Tax | 39.54M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -56.52% in the last 52 weeks. The beta is 0.14, so KoBioLabs's price volatility has been lower than the market average.
| Beta (5Y) | 0.14 |
| 52-Week Price Change | -56.52% |
| 50-Day Moving Average | 3,128.10 |
| 200-Day Moving Average | 4,673.25 |
| Relative Strength Index (RSI) | 43.18 |
| Average Volume (20 Days) | 24,193 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, KoBioLabs had revenue of KRW 75.41 billion and -4.80 billion in losses. Loss per share was -247.40.
| Revenue | 75.41B |
| Gross Profit | 56.49B |
| Operating Income | -8.07B |
| Pretax Income | -4.75B |
| Net Income | -4.80B |
| EBITDA | -5.27B |
| EBIT | -8.07B |
| Loss Per Share | -247.40 |
Balance Sheet
The company has 48.17 billion in cash and 16.78 billion in debt, with a net cash position of 31.38 billion or 1,616.10 per share.
| Cash & Cash Equivalents | 48.17B |
| Total Debt | 16.78B |
| Net Cash | 31.38B |
| Net Cash Per Share | 1,616.10 |
| Equity (Book Value) | 45.42B |
| Book Value Per Share | 1,481.66 |
| Working Capital | 43.72B |
Cash Flow
In the last 12 months, operating cash flow was -2.45 billion and capital expenditures -404.15 million, giving a free cash flow of -2.85 billion.
| Operating Cash Flow | -2.45B |
| Capital Expenditures | -404.15M |
| Depreciation & Amortization | 2.79B |
| Net Borrowing | 2.68B |
| Free Cash Flow | -2.85B |
| FCF Per Share | -146.80 |
Margins
Gross margin is 74.91%, with operating and profit margins of -10.70% and -6.37%.
| Gross Margin | 74.91% |
| Operating Margin | -10.70% |
| Pretax Margin | -6.29% |
| Profit Margin | -6.37% |
| EBITDA Margin | -6.99% |
| EBIT Margin | -10.70% |
| FCF Margin | n/a |
Dividends & Yields
KoBioLabs does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.40% |
| Shareholder Yield | -0.40% |
| Earnings Yield | -8.50% |
| FCF Yield | -5.04% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
KoBioLabs has an Altman Z-Score of -0.3 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.3 |
| Piotroski F-Score | 4 |